RxDoctor Payments Data

Jennifer Bingham, MD

Internal Medicine · Springdale, ARNPI 1609819077

Payments from drug & device makers

$2,752in general payments, 2019–2025

Across 171 payments — averaging $16.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$452
  • AbbVie$386
  • AstraZeneca$336
  • Otsuka America Pharmaceutical, Inc.$269
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$225
  • Novo Nordisk$215
  • plus $868 from 24 others

What the payments were for

  • Food & beverage$2,71199%
  • Education$411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,752 in reported general payments places this provider in the 80th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$28,448
Medicare patients
45
Services billed
251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide29$31,685
JardianceEmpagliflozin19$18,082
TrulicityDulaglutide15$17,918
OzempicSemaglutide16$14,436
EliquisApixaban20$13,499
Buprenorphine36$13,314
Aripiprazole39$6,720
TrintellixVortioxetine Hydrobromide13$5,988
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen149$3,564
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen82$3,474
Duloxetine Hcl40$1,347
Gabapentin94$1,086
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine15$1,056
Potassium Chloride84$988
Tramadol Hcl121$984

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$117$49,60344 claims
Boehringer IngelheimJardiance$452$18,08219 claims
Novo NordiskOzempic$215$14,43616 claims
PfizerEliquis$46$13,49920 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$99$5,98813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Springdale

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →